Additional US Patent Issued for AspirinWorks Test
30 May 2012
Corgenix Medical Corporation, a developer and marketer of diagnostic test kits, has announced that it has been issued an additional U.S. patent covering its AsprinWorks® technology. The AsprinWorks® Test Kit measures thromboxane metabolites in urine to evaluate aspirin effect in apparently healthy individuals.
The U.S. Patent and Trademark Office has issued U.S. Patent No. 8,168,400 on the AspirinWorks Test Kit. The composition-of-matter claims provide intellectual property coverage for the monoclonal antibody that recognizes thromboxane metabolites.
“This patent increases the scope and variety of claims on the AspirinWorks Test Kit,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “By further protecting the AspirinWorks Test we’re strengthening our intellectual property portfolio and enhancing our competitive position in the clinical testing market.”
Asprin is widely prescribed as an anti-platelet drug because of its ability to inhibit thromboxane formation. Thromboxane metabolites are chemicals that activate blood platelets causing them to bind together. This helps to prevent ischemic events such as heart attack and stroke. Corgenix was previously issued a U.S. Patent in 2010 based on the AspirinWorks Test's ability to accurately depict true levels of circulating thromboxane metabolites.
AspirinWorks is the only FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals post ingestion. 11dhTxB2 is a metabolite of thromboxane A2 (TxA2), the target of aspirin therapy. The test targets a potential global market exceeding 200 million individuals.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.
For more information on the AspirinWorks® Test Kit please click on the request information link below.
Related Products
Request Quote for All Products
AspirinWorks Test Kit
CorgenixAspirin is an anti-platelet drug that works to prevent heart attacks and strokes by reducing the production of thromboxane, the chemical that makes platelets sticky. Although we can’t measure thromboxane directly, we can easily and non-invasively measure 11-dehydro thromboxane B2, its chemical biomarker’ using the AspirinWorks Test. In fact, the AspirinWorks Test is the only FDA-cleared test that accurately determines aspirin effect by measuring levels of this biomarker. A low level of the biomarker in the urine means that aspirin is working to reduce thromboxane production. High levels of the biomarker may mean that your dosage of aspirin is not effective for decreasing the risk of a heart attack or stroke, and it’s time for you and your doctor to consider increasing the dose or changing your treatment strategy.